Lantern Pharma’s LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
Lantern Pharma Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its investigational therapy LP-284 for the treatment of soft tissue sarcomas, marking the third such designation for this compound and the sixth across the company’s AI-driven oncology pipeline. This designation expands LP-284’s potential use into solid tumors, addressing a rare cancer with limited treatment options and supporting Lantern’s precision oncology development efforts.
Lantern Pharma’s LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas